 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8990919293949596979899100101» |
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment open, Metastases: To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer (clinicaltrials.gov) - Sep 30, 2014
P1, N=84, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting
- || samotolisib (LY3023414) / Eli Lilly
Enrollment change, Trial primary completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=130, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting N=70 --> 130 | Trial primary completion date: Sep 2014 --> Sep 2016
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
New P3 trial: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Sep 28, 2014
P3, N=450, Not yet recruiting, Sponsor: Eli Lilly and Company
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Sep 22, 2014
P2, N=800, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=70 --> 130 | Trial primary completion date: Sep 2014 --> Sep 2016 Trial primary completion date: Feb 2014 --> Sep 2015
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: MA.17: Letrozole After Tamoxifen in Treating Women With Breast Cancer (clinicaltrials.gov) - Sep 21, 2014
P3, N=5187, Completed, Sponsor: NCIC Clinical Trials Group
Trial primary completion date: Feb 2014 --> Sep 2015 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed, Metastases: Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=14, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Sep 16, 2014
P1/2, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> May 2017
- | Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion: CALGB-40503: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov) - Sep 15, 2014
P3, N=394, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> May 2017 Active, not recruiting --> Completed
- Ibrance (palbociclib) / Pfizer
Phase classification, Combination therapy, Metastases: Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate (clinicaltrials.gov) - Sep 11, 2014
P=N/A, N=0, Available, Sponsor: Pfizer
Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
- | Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment closed: CALGB-40503: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov) - Sep 10, 2014
P3, N=394, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P3 --> P=N/A Completed --> Active, not recruiting
- tamoxifen / Generic mfg.
Biomarker, Trial primary completion date, Monotherapy: PHACS: Pharmacology of Adjuvant Hormonotherapy in Breast Cancer (clinicaltrials.gov) - Sep 9, 2014
P4, N=2000, Recruiting, Sponsor: Institut Claudius Regaud
Completed --> Active, not recruiting Trial primary completion date: May 2013 --> Jun 2018
- Biomarker, Enrollment closed: MIRHO: Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer (clinicaltrials.gov) - Sep 9, 2014
P4, N=39, Active, not recruiting, Sponsor: Institut Claudius Regaud
Trial primary completion date: May 2013 --> Jun 2018 Recruiting --> Active, not recruiting
- ||||| letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
New P2 trial, Metastases: Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) - Aug 29, 2014
P2, N=72, Not yet recruiting, Sponsor: Gynecologic Oncology Group
- || cisplatin / Generic mfg., paclitaxel / Generic mfg.
New P2/3 trial, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Aug 21, 2014
P2/3, N=160, Recruiting, Sponsor: RenJi Hospital
- Firmagon (degarelix) / Astellas, Ferring
Enrollment open: TRial on the Endocrine Activity of Neoadjuvant Degarelix (clinicaltrials.gov) - Aug 19, 2014
P2, N=50, Recruiting, Sponsor: International Breast Cancer Study Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche
New P2 trial: HERAKLES: Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women (clinicaltrials.gov) - Aug 12, 2014
P2, N=132, Not yet recruiting, Sponsor: Gangnam Severance Hospital
- | letrozole / Generic mfg.
Enrollment closed, BRCA Biomarker: LIBER: Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation (clinicaltrials.gov) - Aug 6, 2014
P3, N=386, Active, not recruiting, Sponsor: UNICANCER
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| letrozole / Generic mfg., sorafenib / Generic mfg.
Trial initiation date, Trial primary completion date, Metastases: Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (clinicaltrials.gov) - Jul 30, 2014
P1/2, N=55, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting Initiation date: Mar 2008 --> Aug 2008 | Trial primary completion date: Dec 2014 --> Dec 2015
- Kisqali (ribociclib) / Novartis, buparlisib (AN2025) / Adlai Nortye
Enrollment open, Combination therapy, Metastases: LeeBLet: Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (clinicaltrials.gov) - Jul 26, 2014
P1, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2008 --> Aug 2008 | Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- ||| Herceptin (trastuzumab) / Roche
Enrollment closed: HELEX: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (clinicaltrials.gov) - Jul 24, 2014
P2, N=96, Active, not recruiting, Sponsor: Baylor Breast Care Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) - Jul 21, 2014
P1, N=42, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jul 2014 | Trial primary completion date: Oct 2018 --> Jul 2018
- | Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion, Enrollment change: CALGB-40503: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov) - Jul 16, 2014
P3, N=394, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jul 2014 | Trial primary completion date: Oct 2018 --> Jul 2018 Active, not recruiting --> Completed | N=502 --> 394
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Jul 15, 2014
P1/2, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=502 --> 394 Trial primary completion date: May 2016 --> Dec 2016
- Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy, Metastases: Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate (clinicaltrials.gov) - Jul 14, 2014
P3, N=0, Temporarily Not Available, Sponsor: Pfizer
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Oct 2017 --> Oct 2015
- | New P2 trial, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Jul 14, 2014
P2, N=59, Not yet recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial: Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (clinicaltrials.gov) - Jul 12, 2014
P2, N=20, Not yet recruiting, Sponsor: Sinai Hospital of Baltimore
- letrozole / Generic mfg.
Trial primary completion date: Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer (clinicaltrials.gov) - Jul 10, 2014
P1, N=112, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2017 --> Oct 2015 Trial primary completion date: Sep 2014 --> Jun 2014
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy, Metastases: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=58, Recruiting, Sponsor: Pfizer
Trial primary completion date: Sep 2014 --> Jun 2014 Active, not recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, pictilisib (GDC-0941) / Roche
Trial primary completion date: A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 2, 2014
P1, N=64, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Recruiting Trial primary completion date: Mar 2014 --> Aug 2015
- Piqray (alpelisib) / Novartis
Trial primary completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jun 19, 2014
P1, N=30, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial primary completion date: Mar 2014 --> Aug 2015 Trial primary completion date: Oct 2014 --> Oct 2015
- ||||| Ibrance (palbociclib) / Pfizer
Enrollment closed, IO biomarker, Metastases: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - Jun 18, 2014
P3, N=650, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- || taselisib (GDC-0032) / Roche
Trial primary completion date, Combination therapy, Metastases: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Jun 15, 2014
P1/2, N=332, Recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Feb 2017
- | dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment closed, Combination therapy, Metastases: Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer (clinicaltrials.gov) - Jun 13, 2014
P1/2, N=36, Active, not recruiting, Sponsor: Georgetown University
Trial primary completion date: Jun 2016 --> Feb 2017 Recruiting --> Active, not recruiting
- letrozole / Generic mfg.
Trial primary completion date: Use of High Cost Monitoring During Letrozole Ovulation Induction (clinicaltrials.gov) - Jun 12, 2014
P4, N=21, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2012 --> Mar 2013
- letrozole / Generic mfg.
Enrollment change: Use of High Cost Monitoring During Letrozole Ovulation Induction (clinicaltrials.gov) - Jun 12, 2014
P4, N=21, Completed, Sponsor: University of Michigan
Trial primary completion date: Jul 2012 --> Mar 2013 N=400 --> 21
- letrozole / Generic mfg.
Trial completion: Use of High Cost Monitoring During Letrozole Ovulation Induction (clinicaltrials.gov) - Jun 12, 2014
P4, N=21, Completed, Sponsor: University of Michigan
N=400 --> 21 Active, not recruiting --> Completed
- letrozole / Generic mfg.
Trial primary completion date: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Jun 8, 2014
P2, N=115, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Jun 2015
- letrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Metastases: Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer (clinicaltrials.gov) - Jun 2, 2014
P2, N=60, Recruiting, Sponsor: Xichun Hu
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Jul 2014 --> Dec 2014
- | Kisqali (ribociclib) / Novartis, buparlisib (AN2025) / Adlai Nortye
New P1 trial, Combination therapy, Metastases: LeeBLet: Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (clinicaltrials.gov) - Jun 1, 2014
P1, N=50, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion: AMIGOS: Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation (clinicaltrials.gov) - Jun 1, 2014
P3, N=900, Completed, Sponsor: Yale University
Trial primary completion date: Jul 2014 --> Dec 2014 Active, not recruiting --> Completed
- | letrozole / Generic mfg., everolimus / Generic mfg.
New P1 trial, Metastases: PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) - May 29, 2014
P1, N=42, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy, Metastases: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - May 27, 2014
P1/2, N=58, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Mar 2016
- |||| Ibrance (palbociclib) / Pfizer
Trial primary completion date, IO biomarker, Metastases: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - May 27, 2014
P3, N=650, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2016 --> Mar 2016 Trial primary completion date: Mar 2015 --> Dec 2015
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, IO biomarker, Metastases: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - May 27, 2014
P3, N=650, Recruiting, Sponsor: Pfizer
Trial primary completion date: Mar 2015 --> Dec 2015 Trial completion date: Mar 2016 --> Dec 2016
- ||||| Ibrance (palbociclib) / Pfizer
Enrollment change, IO biomarker, Metastases: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - May 27, 2014
P3, N=650, Recruiting, Sponsor: Pfizer
Trial completion date: Mar 2016 --> Dec 2016 N=450 --> 650
- |||| letrozole / Generic mfg., anastrozole / Generic mfg.
Trial primary completion date: Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (clinicaltrials.gov) - May 18, 2014
P3, N=4160, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=450 --> 650 Trial primary completion date: Apr 2016 --> Dec 2016
- || taselisib (GDC-0032) / Roche
Trial completion date, Combination therapy, Metastases: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - May 18, 2014
P1/2, N=332, Recruiting, Sponsor: Genentech
Trial primary completion date: Apr 2016 --> Dec 2016 Trial completion date: Jun 2016 --> Feb 2017
- ||| letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion date: Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (clinicaltrials.gov) - May 18, 2014
P3, N=4160, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jun 2016 --> Feb 2017 Trial completion date: Apr 2016 --> Dec 2016
- | Ibrance (palbociclib) / Pfizer
New P3 trial, Combination therapy, Metastases: Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate (clinicaltrials.gov) - May 18, 2014
P3, N=0, Available, Sponsor: Pfizer
- || Kisqali (ribociclib) / Novartis
Trial primary completion date: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) (clinicaltrials.gov) - May 15, 2014
P2, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2016 --> Dec 2016 Trial primary completion date: Apr 2014 --> Feb 2015